Skip to main content

Table 3 Disease-related data relation with angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis

From: The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis

  ANGPTL4, ng/ml Apo C3, mg/dl LPL, ng/ml
beta coef. (95% CI), p
Disease-related data    
Disease duration, years −7 (−14–0), 0.058 0.04 (−0.04–0.12), 0.32 4 (0–7), 0.025
CRP, mg/l 1 (−3–5), 0.67 0.05 (0.01–0.10), 0.013 1 (−1–3), 0.46
ESR, mm/1st hour 3 (6 to1), 0.020 −0.00 (−0.03–0.03), 0.93 1 (0–3), 0.033
Rheumatoid factor 18 (−116–153), 0.79 0.2 (−1.2–1.6), 0.77 35 (−28–99), 0.27
ACPA 117 (−12–247), 0.075 0.2 (−1.2–1.5), 0.80 61 (−5–128), 0.068
DAS28-ESR −19 (−93–16), 0.17 −0.4 (−1.0–0.2), 0.18 7 (−18–32), 0.58
DAS28-PCR −15 (−75–45), 0.63 −0.4 (−1.0–0.3), 0.25 2 (−26–30), 0.88
SDAI 0 (−3–4), 0.88 0.03 (−0.01–0.06), 0.17 0 (−1–2), 0.70
CDAI −2 (−10–6), 0.66 −0.08 (−0.16–0.01), 0.069 0 (−3–4), 0.90
HAQ −25 (−128–77), 0.62 −0.3 (−1.4–0.8), 0.60 52 (994), 0.017
Current drugs
 Prednisone 22 (−105–149), 0.73 −0.1 (−1.4–1.3), 0.94 −10 (−69–49), 0.74
 Prednisone, mg/day 16 (−28–59), 0.47 −0.2 (−0.5–0.1), 0.15 1 (−6–7), 0.87
 NSAIDs 21 (−101–144), 0.73 −0.4 (−1.7–0.8), 0.50 9 (−48–66), 0.77
 DMARDs −20 (−181–140), 0.80 −0.4 (−2.1–1.3), 0.63 29 (−53–110), 0.49
 Methotrexate 25 (−105–155), 0.71 0.4 (−0.9–1.8), 0.53 41 (−24–106), 0.21
 Leflunomide −50 (−218–118), 0.56 0.4 (−1.4–2.2), 0.67 51 (−17–119), 0.14
 Hydroxychloroquine 257 (−229–744), 0.30 −3.5 (−8.7–1.6), 0.18 116 (30202), 0.008
 Salazopyrin 150 (−819–1120), 0.76 −3.6 (−13.9–6.6), 0.49 143 (41245), 0.006
 Anti-TNF therapy −11 (−182–159), 0.90 −0.2 (−2.1–1.6), 0.79 101 (33169), 0.004
 Tocilizumab 53 (−204–311), 0.68 −1.3 (−4.0–1.4), 0.35 9 (−118–137), 0.89
 Rituximab −202 (−601–197), 0.32 0.0 (−4.3–4.2), 0.99 −23 (−228–181), 0.82
 Abatacept −182 (−581–217), 0.37 3.9 (−0.3–8.1), 0.069 −58 (−263–146), 0.58
 JAK inhibitors 347 (−22–715), 0.065 −3.6 (−7.5–0.3), 0.072 −39 (−216–139), 0.67
History of extraarticular manifestations −136 (−349–76), 0.21 0.4 (−1.9–2.7), 0.76 37 (−54–127), 0.42
Erosions 17 (−122–157), 0.81 −1.0 (−2.4–0.4), 0.16 57 (−7–121), 0.081
  1. NSAID nonsteroidal anti-inflammatory drugs, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, Obesity, ESR erythrocyte sedimentation rate, DAS28 Disease Activity Score in 28 joints, CRP C-reactive protein, ACPA anti-citrullinated protein antibodies, CDAI Clinical Disease Activity Index, SDAI Simple Disease Activity Index, HAQ Health Assessment Questionnaire